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Abstract
This study presents sample size considerations derived from the Efficacy of Thromboprophylaxis as an Intervention during
Gravidity (EThIGII) trial (ClinicalTrials.gov: NCT00400387) to address the question of low-molecular-weight heparin (LMWH)
treatment in women with recurrent pregnancy loss (RPL) depending on the M2/ANXA5 haplotype. To evaluate the possible
influence of such treatment on miscarriage rates of trial participants, a post hoc analysis of ANXA5 promoter genotypes in the
light of M2/ANXA5 (RPRGL3) distribution was performed using logistic models. DNA for genotyping was available from 129
LMWH and 95 control patients, 44 (19.6%) of whom were M2/ANXA5 carriers. Miscarriages occurred in 1 (4.0%) of 25 M2/
ANXA5 carriers from the LMWH group compared to 4 (21.1%) of 19 in the control group, resulting in an odds ratio (95%
confidence interval) for miscarriage of 0.16 (0.016-1.5) for women treated with LMWH. In noncarriers, miscarriage rates were 6
(5.8%) of 104 versus 7 (9.2%) of 76 for the LMWH and the control groups, respectively, corresponding to an odds ratio for
miscarriage of 0.60 (0.19-1.9). The apparent beneficial effects of miscarriage rate reduction in M2/ANXA5 carriers with RPL
concur with biological considerations about improvement in reduced ANXA5 function through LMWH treatment in an adequate
murine model. The data obtained were instrumental to design proper assessment of the existence and magnitude of this effect.
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Introduction
Hereditary thrombophilia may well be one etiology for recur-
rent pregnancy loss (RPL),1 and evidence on impeded placental
perfusion shows an increased risk for adverse pregnancy out-
come.2-5 The influence of genetic thrombophilia has been
reviewed in several clinical studies6 and initially concentrated
mostly on the common, low thrombotic risk factor V Leiden
(G1691A, R506Q, and rs6025) and prothrombin (PTm)
G20210A (rs1799963) variants.7 In 2007, another potential
hereditary factor for thrombophilia-related RPL was found,
termed as ‘‘M2,’’ a haplotype in the proximal core promoter
region of the annexin A5 (ANXA5) gene, defined as a constel-
lation of 4 single-nucleotide polymorphisms (SNPs),
c.467G>A, rs112782763; c.448A>C, rs28717001;
c.422T>C, rs28651243; and c.373G>A, rs113588187.8 The
haplotype, a risk factor for RPL susceptibility, RPRGL3,
OMIM entry 614391, was confirmed through molecular clon-
ing and direct sequencing of the relevant amplicon clones, so
the minor alleles of all 4 SNPs comprising it were proven to
reduce the expression of a reporter gene in a functionally rep-
resentative cell line compared to a background construct har-
boring all the major (normal) alleles.8 Reduction in ANXA5
messenger RNA abundance was demonstrated in chorion-
carrying M2,9 which was confirmed to be haplotype specific,10
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and concomitant decrease in ANXA5 protein levels has been
detected in placental tissue of M2 carriers with a thrombophilic
placental complication.11 Differential enrichment of the haplo-
type has been observed in RPL patient-groups, contributing to
relative risks for carriers from 1.5 to 2, compared to random
population controls of German,5,8 Bulgarian,5 and Malaysian12
ethnic backgrounds. Estimated relative risks in M2 carriers in
relation to healthy control patients with negative history for
infertility or miscarriage are between 1.8 and 3, depending
on the number of miscarriages and categories of recurrent spon-
taneous abortion and embryonic development in patient
cohorts of German,5,8 Italian,4 Bulgarian,5 and Japanese13
extraction. In Germany alone, the RPL risk attributed to M2
carriers of retrospective and prospective clinical cohorts has
been estimated in altogether 600 recurrent miscarriage patients
and 1123 control individuals.5,8,14-17 In 2012, another haplo-
type classification system H1 to Hn was introduced to charac-
terize nucleotide variations in the 50 nontranslated region of
ANXA5,18 including altogether 7 SNPs, rs62319820,
rs112782763, rs28717001, rs28651243, rs113588187,
rs1050606, and rs1131239, resulting in 4 to 7 constructed hap-
lotype combinations, depending on genotyping scope and
depth in Dutch patients.18-20 According to this classification,18
haplotype H3 would represent an expansion of M2, including
the minor alleles of rs62319820 upstream and of rs1050606 and
rs1131239 downstream. The association of M2 with the down-
stream SNPs rs1050606 and rs1131239 of uncertain functional
relevance is apparently not perfect, as evident from previous8
and more recent studies.15,20 Since M2/ANXA5 is linked with
reduced expression of ANXA5 in chorionic placenta,10,11 the
associated comparable risks of male carriers in RPL couples
may indicate impaired embryonic anticoagulant function.5,12,14
This is in accordance with the well-studied role of ANXA5 as
placental anticoagulant, enriched on the surface of chorionic
syncytiotrophoblasts.1
As RPL constitutes huge psychological stress to the couples,
different therapeutic options have been evaluated and dis-
cussed. A number of observational studies suggested that
low-molecular-weight heparin (LWMH) increases live birth
rates.21-25 Results of 2 earlier randomized trials demonstrated
the efficacy of LMWH for women with unexplained RPL.26,27
In contrast, 3 later studies did not confirm these findings.28-30
Conclusions of a study comparing LMWH to aspirin drew no
significant advantage of LWMH versus aspirin.31 However,
these studies differ considerably in their selection of potential
genetic conditions associated with RPL. A recent observational
study in factor V Leiden (FVL)- and PTm-carrying RPL
women demonstrated benefits of LMWH treatment in terms
of fewer fetal deaths, less preeclampsia cases, and lower rate
of small for gestational age babies.32 The last Cochrane review
on anticoagulant treatment in women with unexplained recur-
rent miscarriage with or without inherited thrombophilia con-
cluded that the effect of such treatment in women with
hereditary thrombophilia ‘‘needs to be assessed in further ran-
domized controlled trials.’’33 To meet the need for properly
powered, multicenter, randomized assessment, the Efficacy
of Thromboprophylaxis as an Intervention during Gravidity
(EThIGII) trial planned to enroll 486 patients (expecting a
10% dropout rate), and it took >5 years and much effort to
attain this goal. This then permitted the rare opportunity of
performing a post hoc analysis of genetic RPL predisposition
factors from retrospective DNA samples. The EThIGII trial
compared LMWH and multivitamins versus multivitamins
alone in unexplained RPL.33 The authors concluded that
LMWH had no influence on ongoing pregnancies or live birth
rates. Additionally, in this trial, a subgroup analysis evaluating
RPL patients (n ¼ 63) with inherited thrombophilia (FVL or
PTm mutations, antithrombin deficiency, protein C deficiency,
and protein S deficiency) was performed. Low-molecular-
weight heparin and multivitamins showed no significant advan-
tage versus multivitamins alone in this particular patient-group.
However, the number of women with each of the above throm-
botic risk factors or their combinations was fairly small, so that
further stratification did not appear meaningful. When the trial
was designed, M2/ANXA5 had not been identified as a possible
RPL risk factor. Given the uncertain effect of LMWH on RPL
carriers of genetic thrombophilia, it was of interest to examine
a possible therapeutic influence on women carrying the M2
haplotype of the ANXA5 gene as a predisposition factor with
a prevalence of 10% to 15% in European parous controls with-
out miscarriages.4,5,8,14 With experimental evidence coming
from a heterozygous knockout murine model of AnxA5 func-
tion, LMWH could substitute for reduced abundance of
ANXA5 as anticoagulant on relevant molecular targets.34
Materials and Methods
Trial Design
The EThIGII was a multicenter, randomized, controlled, and
open-label trial.35 The trial protocol and subsequent genetic
analysis for ‘‘possible predisposing hereditary factors’’
approval was obtained from the federal authorities in Germany
and Austria and the ethics boards of all attending trial sites. All
patients signed written informed consent for trial participation.
The study randomized 449 women without indication for
LMWH use, such as homozygous FVL or factor II mutations,
and observed a further 112 women, of whom, in total, 228
provided informed consent for the use of their genomic DNA
to study potential inherited RPL factors. Four women were lost
to follow-up, and from the remaining 224 patients, 95 were
randomly assigned to the control and 94 to the intervention
arm. A further 35 received LMWH but were not randomized,
10 of whom had antiphospholipid syndrome, 18 of whom had
had problems related to venous thromboembolisms, and 5 who
would have been eligible but chose to use LMWH.
Definitions of Parameters and Outcomes
‘‘Early RPL’’ was defined as at least 2 consecutive miscar-
riages before 12 weeks’ gestation, and women with 1 or more
‘‘late’’ miscarriages (after 12 weeks’ gestation) were also
included. Main outcomes were intact pregnancy at 24 weeks’
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gestation and live birth according to the birth records. These
records were also used to assess the secondary outcomes pre-
eclampsia, placental abruption, preterm delivery <37th gesta-
tional week, or intrauterine growth restriction <5th percentile
according to Voigt et al.36 ‘‘Miscarriage’’ refers herein to spon-
taneous pregnancy loss before 24 weeks’ gestation.
Genotyping of ANXA5 Proximal Promoter Region
Presence of the common M2 haplotype in the annexin A5
gene (M2/ANXA5) was assessed in genomic DNA of 224
enrolled patients upon trial completion. DNA was extracted
from 1 mL peripheral blood, and genotyping of ANXA5 pro-
moter haplotypes was performed by amplicon sequencing as
described by Bogdanova et al.8 Accuracy of genotyping was
verified by randomly blinded inclusion of 2% repeated sam-
ples. Genotypes were scored in table format and 4 digits coded
for further processing.
Statistical Methods
The analyses presented here were all decided upon at the outset
of this add-on project to the EThIGII trial and before any gen-
otyping data were collected. All assessments were carried out
using the R statistical software package version 3.1.0,37 and all
tests were considered significant for P  .05. Tests for con-
tingency tables used the w2 test without continuity correction or
the Fisher test if expected counts were below 5. The signifi-
cance for differences between subgroups was tested based on
the interaction term in a logistic model. Odds ratios (ORs) and
confidence intervals (CIs) were estimated from the logistic
model if a category had 3 or more levels or using a Wald
estimate and normal approximation using the ‘‘odds ratio’’
command from the ‘‘epitools’’ package.38
Departures from the Hardy-Weinberg equilibrium were
assessed using the ‘‘genetics’’ package.39 Statistical power cal-
culations were performed with the ‘‘pwr’’ package.40
Results
A total of 224 patients agreed to DNA genotyping for potential
hereditary RPL factors, 129 of whom received LMWH and 95
who did not (see Table 1). The observed prevalence of M2
carriers was 19.6% and did not differ markedly between the
groups, with 20.0% versus 19.4% in control and LMWH,
respectively. M1 carriers were also similar between the groups
(13.7% vs 13.2%). M2/ANXA5 carrier rates were also examined
in the clinical subgroups with 3 or more pregnancy losses and 3
or more early pregnancy losses and were essentially the same at
20.7% and 23.5% (see Table 2). When compared to 533 con-
trols from the German population,8 the observed OR for being
an M2 carrier in the EThIGII sample was a modest 1.3 (95%
CI, 0.89-2.0) in contrast to a comparison with 500 German
parous controls without miscarriages,8 where the OR was 2.7
(1.7-4.3; see Figure 1). Miscarriage rates of M2 carriers and
noncarriers in both intervention groups and clinically relevant
subgroups were compared (Table 2). M2 carriers in the control
groups exhibited higher miscarriage rates compared to the M2
noncarriers with an OR of 2.6 (95% CI, 0.6-10), with similar
results for the subgroups, although all differences are not
significant.
The ORs for having a miscarriage depending on the inter-
vention (LMWH vs control) do not depend significantly on
whether one is an M2 carrier. Nonetheless, it is noteworthy
that for M2 carriers, LMWH appears more protective with an
OR of 0.16 (95% CI, 0.016-1.5) than for noncarriers with an
OR of 0.60 (95% CI, 0.19-1.9; see Figure 1).
M2 carriers treated with LMWH have roughly equal
chances of miscarriage compared to treated noncarriers, with
an OR of 0.76 (95% CI, 0.03-4.9). For untreated patients, the
OR for miscarriage in carriers versus noncarriers is 2.6 (95%
CI, 0.6-10). The same direction for the effect was seen in the
subgroups of patients with 3 or more abortions and 3 or more
early spontaneous abortions, where the LMWH M2 carriers
had no miscarriages, but the numbers were extremely small
(Table 2).




Genotype Observed Expectedc Observed Expected Observed Expected
N/N 154 (68.8%) 67.8% 64 (67.4%) 67.4% 90 (69.8%) 68.2%
N/M1 26 (11.6%) 11.0% 12 (12.6%) 11.2% 14 (10.9%) 10.9%
M1/M1 0 (0%) 0.5% 0 (0%) 0.5% 0 (0%) 0.4%
N/M2; M1/M2d 35; 4 (17.4%) 19.5% 16; 1 (17.9%) 19.7% 19; 3 (17.1%) 19.3%
M2/M2 5 (2.2%) 1.2% 2 (2.1%) 1.2% 3 (2.3%) 1.2%
M2 carriers 19.6% 20.7% 20.0% 20.9% 19.4% 20.5%
Total 224a 100% 95 100% 129 100%
Abbreviations: EThIGII, Efficacy of Thromboprophylaxis as an Intervention during Gravidity; LMWH, low-molecular-weight heparin; RPL, recurrent pregnancy
loss.
aAvailable patients: patients with available DNA samples.
bLow-molecular-weight heparin-treated patients.
cExpected: genotype frequency expected at Hardy-Weinberg equilibrium.
dGenotype M1/M2 was only observed in 4 patients, 1 of the control arm and 3 of the intervention/observation arms.
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An evaluation of further subgroups including the LMWH
effect on treated M2 carriers versus controls with late preg-
nancy losses was not performed because all haplotype-
carrying patients (n ¼ 4) were in the intervention arm of the
trial and had no miscarriages. Likewise, noncarrier groups of
late pregnancy loss patients in both trial arms were rather small
to allow for a formal comparison. A comparable situation arose
when evaluating secondary outcomes because the rates of
preeclampsia and intrauterine growth restriction were alto-
gether under 5%, rendering a meaningful analysis impossible.
The rate of premature births was similarly low in both trial
arms and comparable to that of the general population in
Germany and Austria.41
Genotyping the significant patient sample of the EThIGII
trial resulted in 44 M2/ANXA5 carriers distributed about
equally in both trial arms, with slight prevalence of the treated
Table 2. Miscarriages at 24 Weeks’ Gestation Are Provided as Counts (Percentages) Depending on M2 Carrier Status in the Control and
Intervention Groups.a
All Patients (N ¼ 224) Both Groups Control LMWHb P Value (Control vs LMWH)
M2 carriers 5/44 (11.4%) 4/19 (21.1%) 1/25 (4.0%) .15
M2 noncarriers 13/180 (7.2%) 7/76 (9.2%) 6/104 (5.8%) .38
3 Losses (N ¼ 82)
M2 carriers 2/17 (11.8%) 2/11 (18.2%) 0/6 (0%) .51
M2 noncarriers 6/67 (9.0%) 3/29 (10.3%) 3/38 (7.9%) .55
3 Early losses (N ¼ 68)
M2 carriers 2/16 (12.5%) 2/11 (18.2%) 0/5 (0%) 1.0
M2 noncarriers 5/54 (9.3%) 3/25 (12.0%) 2/29 (6.9%) .65
Abbreviation: LMWH, low-molecular-weight heparin.
aSubgroups are presented with 3 or more losses and 3 or more early losses.
bPatients treated with low-molecular-weight heparin.
Figure 1. Forest plot to the odds ratios of the outcomes ‘‘M2 carrier status’’ in EThIGII patients versus population and parous controls, and
‘‘miscarriage’’ in the LMWH-treated versus vitamins-treated (control) groups, respectively, among M2 carriers versus noncarriers.
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group (Tables 1 and 2). These incidence data point at an M2
carrier rate of roughly 20% for similar trials. In order to
achieve 80% statistical power in detecting a difference in
miscarriage rates of 15% and 25%, about 250 M2 carriers
per arm would be required in a prospective study. This result
expands the number of required participants to 2500 for RPL
women of European descent.
Discussion
Until recently, no study has assessed the efficacy of anticoa-
gulant treatment in carriers of the M2/ANXA5 haplotype. The
samples available from the EThIGII trial made it possible to
evaluate the influence of LMWH therapy on M2 carriers
among RPL patients (n ¼ 44) compared to noncarriers (n ¼
180). Although the M2 carrier rate of 19.6% in the EThIGII
patient sample was higher than the generally estimated 10% to
15% for European parous controls without miscarriages, it was
on the low side for RPL patient cohorts, where prevalence of
21% to 29% has been observed depending on the number of
consecutive early embryonal losses.4,5,8,14 This minor devia-
tion could be easily explained by the EThIGII study design,
which included patients with single or multiple late fetal losses,
since M2/ANXA5 does not appear to be a risk factor for
repeated late spontaneous abortions.4,5 M2 carrier rates were
somewhat higher in the subgroups of patients with 3 or more
pregnancy losses and 3 or more early pregnancy losses, where
they were 20.7% and 23.5%, respectively. Based on the liter-
ature,4,5,8,12,13 one would expect a risk ratio of 1.2 to 1.6 for
miscarriage in M2 carriers versus noncarriers, corresponding to
an OR of 1.2 to 1.7 for a miscarriage rate of 12%. These
previous estimates are slightly lower than the value of 2.6 when
comparing miscarriage rates of M2 carriers to noncarriers of
the trial’s control group, which however had a wide CI.
An OR for miscarriage of 0.16 (95% CI, 0.016-1.5) in M2
carriers treated with LMWH was observed compared to the
controls. One might suppose that such a strong effect would
be noticeable in trials published so far. However, given a mis-
carriage rate of, say, 15% in a control population, a carrier
prevalence of 20%, and a 5-fold risk reduction for carriers
using LMWH, then the intervention arm would have a miscar-
riage rate of 12.6% and a trial with 450 women would have a
power of only 11% for detecting this difference. It is thus
conceivable that a strong effect exists, which has not been
detected in published trials.
Recurrent pregnancy loss is often defined as a condition
with 3 or more consecutive pregnancy losses, but the EThIGII
trial design was to include women with 2 or more consecutive
miscarriages according to the current definitions used by the
American Society for Reproductive Medicine42 and other com-
parable trials in the field. This definition takes into account a
greater demand of medical attention after 2 miscarriages, on
the other hand, a more pronounced effect of LMWH for women
at higher risk is conceivable. The comparative analysis of M2
carriers with a history of 3 or more miscarriages and 3 or more
early miscarriages supported this notion and is an addition to
previous research demonstrating the higher carrier rates of the
haplotype in such RPL patients4,15 and suggesting a biological
role in early embryonic anticoagulation.5,12 In contrast, no
effect of LMWH on live birth rates of noncarriers of M2 could
be observed.
Genotyping a significant patient sample of the EThIGII trial
and comparing the effects of LMWH on M2/ANXA5 carriers
versus noncarriers provide data for exploring a potential effi-
cacy of treatment in this particular patient-group, suggesting
that a proposed benefit in M2 carriers should be assessed in
adequately powered trials. Considering the time, logistics,
material, and organizational effort such endeavor would
involve, this would require a large multinational coordinated
study. Alternatively, or parallel to this, such study could be
designed with a different source population. Thus, the results
of post hoc analysis of the EThIGII trial provide rare data that
can help begin to shed light on this issue and assist in the
planning of larger trials.
Altogether, although differences were not significant, it
is worth considering that in the relevant subgroups with 3
or more losses/early losses, M2 carriers of the control
sample had consistently greater miscarriage risks compared
to noncarriers and that treated M2 carriers always had
better live birth rates (at 100%) than nontreated carriers
(Table 2 and Figure 1). In other words, genetic data of
this trial are consistent with a strong protective effect of
LMWH for M2/ANXA5 carriers, similar to a response
obtained in an AnxA5 maternally deficient murine model,34
but numbers are too low to be certain.
Considering an incidence of 15% to 17% for the M2 haplo-
type in ANXA5 among Europeans and a plausible improve-
ment in live birth and thrombophilia-related obstetric
complication rates in LMWH-treated pregnant women of
M2-carrying couples, it would be an approach of personalized
medicine to provide diagnostic care and relevant medication to
a population at risk.
In conclusion, there are biological and mechanistic reasons
for supposing that M2/ANXA5 carriers may benefit from
LMWH treatment. We present evidence that points in this
direction, but the existence and magnitude of the effect has yet
to be determined.
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